Latest & greatest articles for fluoxetine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on fluoxetine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on fluoxetine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for fluoxetine

1. Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial (Full text)

Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID (...) . doi: 10.1016/S1474-4422(20)30207-6. Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial Collaborators Expand Collaborators AFFINITY Trial Collaboration

2020 EvidenceUpdates PubMed abstract

2. Fluoxetine

Fluoxetine Terms of use - Canada.ca Language selection Search Search Canada.ca Search Topics menu Main Menu You are here: Terms of use From These Terms of Use govern the access and use of Clinical Information released by Health Canada for non-commercial purposes. By clicking the button “I agree” and accepting these Terms of Use and upon being granted access to the Clinical Information, you, and, if applicable, the organization on behalf of which you are accessing the Clinical Information

2020 Health Canada - drugs and medical devices

3. Fluoxetine to improve functional outcomes in patients after acute stroke: the FOCUS RCT (Full text)

Fluoxetine to improve functional outcomes in patients after acute stroke: the FOCUS RCT Fluoxetine to improve functional outcomes in patients after acute stroke: the FOCUS RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue (...) }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Fluoxetine taken daily for 6 months after acute stroke did not improve patients' functional outcome. {{author}} {{($index , , , , , , , , & . Martin Dennis 1, * , John Forbes 2 , Catriona Graham 3 , Maree Hackett 4 , Graeme J Hankey 5 , Allan House 6 , Stephanie Lewis 7 , Erik Lundström 8, 9 , Peter Sandercock 1 , Gillian Mead 1 1 Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK 2 Health Research Institute

2020 NIHR HTA programme PubMed abstract

4. Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT (Full text)

Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try (...) a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Amiloride, fluoxetine and riluzole were not effective in reducing the brain volume loss in people with secondary progressive MS over 96 weeks. {{author}} {{($index , , , , , , , , , , , , , , , , , , , , , , , , , , & . Floriana De Angelis 1 , Peter Connick 2 , Richard A Parker 3 , Domenico Plantone 1 , Anisha Doshi 1 , Nevin John 1 , Jonathan

2020 NIHR HTA programme PubMed abstract

5. Inflammatory modulation of fluoxetine use in patients with depression: A systematic review and meta-analysis. (Abstract)

Inflammatory modulation of fluoxetine use in patients with depression: A systematic review and meta-analysis. There is growing evidence that there is a relationship between major depressive disorder (MDD), also simply known as "depression", and inflammatory processes. Selective serotonin inhibitors, such as fluoxetine, are used as a first-line treatment for depression, and it is hypothesized that its use can reduce levels of proinflammatory cytokines. The aim of this systematic review and meta (...) -analysis is to enable a better understanding of how treatment with the antidepressant fluoxetine modulates inflammation, and the roles of the main cytokines in this process. Risk of bias (RoB) in the included studies was assessed using the Cochrane Risk of Bias Assessment tool for Non-randomized studies (RoBANS). In the meta-analysis, standardized mean difference (SMD) was used as a summary statistic and grouped statistics using the generic inverse variation method in RevMan 5 with random effects model

2020 Cytokine

6. The impact of CYP2D6 mediated drug-drug interaction: a systematic review on a combination of metoprolol and paroxetine/fluoxetine. (Full text)

The impact of CYP2D6 mediated drug-drug interaction: a systematic review on a combination of metoprolol and paroxetine/fluoxetine. Metoprolol (a CYP2D6 substrate) is often co-prescribed with paroxetine/fluoxetine (a CYP2D6 inhibitor) because the clinical relevance of this drug-drug interaction (DDI) is still unclear. This review aimed to systematically evaluate the available evidence and quantify the clinical impact of the DDI.Pubmed, Web of Science, Cochrane Library and Embase were searched

2020 British journal of clinical pharmacology PubMed abstract

7. Fluoxetine in acute treatment of children and adolescents with obsessive-compulsive disorder: a systematic review and meta-analysis. (Abstract)

Fluoxetine in acute treatment of children and adolescents with obsessive-compulsive disorder: a systematic review and meta-analysis. Background: Obsessive-compulsive disorder (OCD) is a common psychiatric illness in children and adolescents. Previous evidence suggests that fluoxetine is effective in the treatment of OCD in children and adolescents. However, those studies had small sample sizes. As a result, a systematic review, which is a more powerful method to calculate the true effect size (...) , can be applied to examine the efficacy, acceptability and tolerability of fluoxetine in the treatment of OCD in children and adolescents.Objectives: The aims of this study were to review the efficacy, acceptability and tolerability of fluoxetine in the treatment of OCD in children and adolescents.Study appraisal and synthesis methods: The titles and abstracts collected from electronic databases were evaluated. Then, the full-text versions of relevant studies were thoroughly assessed

2020 Nordic journal of psychiatry

8. Efficacy and Safety of Fluoxetine in Autism Spectrum Disorder: A Meta-analysis. (Abstract)

Efficacy and Safety of Fluoxetine in Autism Spectrum Disorder: A Meta-analysis. 30950834 2019 11 20 1536-3686 2019 Apr 02 American journal of therapeutics Am J Ther Efficacy and Safety of Fluoxetine in Autism Spectrum Disorder: A Meta-analysis. 10.1097/MJT.0000000000000978 Li Cheng C Department of Pediatrics, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China. Bai Yongqi Y Department of Pediatrics, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan

2019 American journal of therapeutics

9. Effect of Fluoxetine on Obsessive-Compulsive Behaviors in Children and Adolescents With Autism Spectrum Disorders: A Randomized Clinical Trial. (Full text)

Effect of Fluoxetine on Obsessive-Compulsive Behaviors in Children and Adolescents With Autism Spectrum Disorders: A Randomized Clinical Trial. Selective serotonin receptor inhibitors are prescribed to reduce the severity of core behaviors of autism spectrum disorders, but their efficacy remains uncertain.To determine the efficacy of fluoxetine for reducing the frequency and severity of obsessive-compulsive behaviors in autism spectrum disorders.Multicenter, randomized, placebo-controlled (...) clinical trial. Participants aged 7.5-18 years with autism spectrum disorders and a total score of 6 or higher on the Children's Yale-Brown Obsessive Compulsive Scale, modified for pervasive developmental disorder (CYBOCS-PDD) were recruited from 3 tertiary health centers across Australia. Enrollment began November 2010 and ended April 2017. Follow-up ended August 2017.Participants were randomized to receive fluoxetine (n = 75) or placebo (n = 71). Study medication was commenced at 4 or 8 mg/d

2019 JAMA PubMed abstract

10. Fluoxetine for stroke recovery: Meta-analysis of randomized controlled trials. (Full text)

Fluoxetine for stroke recovery: Meta-analysis of randomized controlled trials. To determine whether fluoxetine, at any dose, given within the first year after stroke to patients who did not have to have mood disorders at randomization reduced disability, dependency, neurological deficits and fatigue; improved motor function, mood, and cognition at the end of treatment and follow-up, with the same number or fewer adverse effects.Searches (from 2012) in July 2018 included databases, trials (...) to the seven trials identified in a 2012 Cochrane review (total: 13 trials, n = 4145). There was no difference in the proportion independent (3 trials, n = 3249, 36.6% fluoxetine vs. 36.7% control; RR 1.00, 95% confidence interval 0.91 to 1.09, p = 0.99, I2 = 78%) nor in disability (7 trials n = 3404, SMD 0.05, -0.02 to 0.12 p = 0.15, I2 = 81%) at end of treatment. Fluoxetine was associated with better neurological scores and less depression. Among the four (n = 3283) high-quality RCTs, the only difference

2019 International journal of stroke : official journal of the International Stroke Society PubMed abstract

11. Fluoxetine for adults who are overweight or obese. (Abstract)

Fluoxetine for adults who are overweight or obese. Fluoxetine is a serotonin reuptake inhibitor indicated for major depression. It is also thought to affect weight control: this seems to happen through appetite changes resulting in decreased food intake and normalisation of unusual eating behaviours. However, the benefit-risk ratio of this off-label medication is unclear.To assess the effects of fluoxetine for overweight or obese adults.We searched the Cochrane Library, MEDLINE, Embase, LILACS (...) , the ICTRP Search Portal and ClinicalTrials.gov and World Health Organization (WHO) ICTRP Search Portal. The last date of the search was December 2018 for all databases, to which we applied no language restrictions .We included randomised controlled trials (RCTs) comparing the administration of fluoxetine versus placebo, other anti-obesity agents, non-pharmacological therapy or no treatment in overweight or obese adults without depression, mental illness or abnormal eating patterns.Two review authors

2019 Cochrane

12. Does fluoxetine improve recovery after stroke? (Abstract)

Does fluoxetine improve recovery after stroke? The studyFOCUS Trial Collaboration. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. Lancet 2019;393:256-74.The study was funded by the UK Stroke Association and the NIHR Health Technology Assessment Programme project number 13/04/30.To read the full NIHR Signal, go to: https://discover.dc.nihr.ac.uk/content/signal-000729/a-commonly-used-antidepressant-doesnt-improve

2019 BMJ Controlled trial quality: predicted high

13. Effectiveness and safety of fluoxetine for premature ejaculation: Protocol for a systematic review. (Full text)

Effectiveness and safety of fluoxetine for premature ejaculation: Protocol for a systematic review. Premature ejaculation (PE) is one of the most common male sexual dysfunctions, which can directly harm men's self-esteem and affect the stability of the relationship between husband and wife. To some extent, PE even affects the harmony and stability of society. So, men's health has gained more and more attention. As one of the long-acting selective serotonin reuptake inhibitors (SSRIs (...) ), fluoxetine has been proven to be effective in the treatment of PE by many trails. In this study, we aim to evaluate the effectiveness and safety of fluoxetine for PE to provide the newest evidence for clinical use.Literature research will be divided into 2 parts: electronic search and manual search. We will search PubMed, EMBASE, The Cochrane Library, the China National Knowledge Infrastructure (CNKI), China Biology Medicine disc (CBMdisc), the China Science and Technology Journal database (VIP

2019 Medicine PubMed abstract

14. General Medicine: Routine fluoxetine in stroke

General Medicine: Routine fluoxetine in stroke Routine fluoxetine in stroke | BMJ Evidence-Based Medicine Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Routine fluoxetine (...) in stroke Article Text EBM Verdict General Medicine Routine fluoxetine in stroke Carl Heneghan 1 , Kamal R Mahtani 2 Statistics from Altmetric.com A recent UK trial addressed whether routine use of fluoxetine in patients who had a stroke improved motor recovery at 6 months. EBM Verdict EBM Verdict on: Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. FOCUS Trial Collaboration. Lancet 2019;393:265–74. doi: 10.1016/S0140-6736

2019 Evidence-Based Medicine

15. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. (Full text)

Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. Results of small trials indicate that fluoxetine might improve functional outcomes after stroke. The FOCUS trial aimed to provide a precise estimate of these effects.FOCUS was a pragmatic, multicentre, parallel group, double-blind, randomised, placebo-controlled trial done at 103 hospitals in the UK. Patients were eligible if they were aged 18 years or older, had (...) a clinical stroke diagnosis, were enrolled and randomly assigned between 2 days and 15 days after onset, and had focal neurological deficits. Patients were randomly allocated fluoxetine 20 mg or matching placebo orally once daily for 6 months via a web-based system by use of a minimisation algorithm. The primary outcome was functional status, measured with the modified Rankin Scale (mRS), at 6 months. Patients, carers, health-care staff, and the trial team were masked to treatment allocation. Functional

2018 Lancet Controlled trial quality: predicted high PubMed abstract

16. Long term effects of neonatal exposure to fluoxetine on energy balance: A systematic review of experimental studies. (Abstract)

Long term effects of neonatal exposure to fluoxetine on energy balance: A systematic review of experimental studies. Serotonin exerts a modulating function on the development of the central nervous system, including hypothalamic circuits controlling feeding behavior and energy expenditure. Based on the developmental plasticity theory, early disturbances of synaptic availability of serotonin may promote phenotypic adaptations and late disorders of energy balance regulation leading to obesity (...) and associated diseases. The aim of this systematic review is to determine the effects of pharmacological neonatal inhibition of serotonin reuptake by fluoxetine, on parameters related to feeding behavior and energy balance. Literature searches were performed in Medline/PubMed and Lilacs databases, out of which 9726 studies were found. Using predefined protocol and registered on CAMARADES website, 23 studies were included for qualitative synthesis. The internal validity was assessed using the SYRCLE's risk

2018 European journal of pharmacology

17. Fluoxetine

Fluoxetine Top results for fluoxetine - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2 (...) ) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for fluoxetine The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms

2018 Trip Latest and Greatest

18. The efficacy comparison of citalopram, fluoxetine, and placebo on motor recovery after ischemic stroke: a double-blind placebo-controlled randomized controlled trial (Abstract)

The efficacy comparison of citalopram, fluoxetine, and placebo on motor recovery after ischemic stroke: a double-blind placebo-controlled randomized controlled trial The present study aimed to assess the effectiveness of oral citalopram, compared with fluoxetine and a placebo, in patients with post-stroke motor disabilities.A randomized double-blind placebo-controlled clinical trial was conducted between January 2015 and January 2016.The neurology department of a university-affiliated urban (...) hospital in Tehran, Iran.Ninety adult patients with acute ischemic stroke, hemiplegia, or hemiparesis and a Fugl-Meyer Motor Scale score of below 55 were included.Participants were randomly allocated to one of three groups: Group A received 20 mg PO of fluoxetine daily, Group B received 20 mg PO of citalopram daily, and Group C received a placebo PO The duration of the therapy was 90 days. In addition to the medications, all of the participants received physiotherapy.Functional status at 90 days, which

2018 EvidenceUpdates

19. The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical and health economic analysis plan for the trials and for the individual patient data meta-analysis. (Full text)

The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical and health economic analysis plan for the trials and for the individual patient data meta-analysis. Small trials have suggested that fluoxetine may improve neurological recovery from stroke. FOCUS, AFFINITY and EFFECTS are a family of investigator-led, multicentre, parallel group, randomised, placebo-controlled trials which aim to determine whether the routine administration (...) of fluoxetine (20 mg daily) for six months after an acute stroke improves patients' functional outcome.The core protocol for the three trials has been published (Mead et al., Trials 20:369, 2015). The trials include patients aged 18 years and older with a clinical diagnosis of stroke and persisting focal neurological deficits at randomisation 2-15 days after stroke onset. Patients are randomised centrally via each trials' web-based randomisation system using a common minimisation algorithm. Patients

2018 Trials PubMed abstract

20. Model-based comparing efficacy of fluoxetine between elderly and non-elderly participants with major depressive disorder. (Abstract)

Model-based comparing efficacy of fluoxetine between elderly and non-elderly participants with major depressive disorder. The high heterogeneity was existed among the studies of the elderly participants with major depressive disorder (MDD), which may lead to incorrect conclusions in the previous meta-analysis. This study used model based meta-analysis to compare the efficacy of fluoxetine between the elderly and non-elderly participants with MDD and to explain the heterogeneity among (...) the studies.A comprehensive literature search was conducted in the public databases, involving utilization of fluoxetine for treating MDD in the acute-phase. The time-efficacy model was established based on the changes of the Hamilton Depression Rating Scale (HDRS) score compared to baseline level. The efficacy features and related factors of fluoxetine in the elderly participants were investigated by comparing with the non-elderly population.Sixty-one studies encompassing 4058 participants were included

2018 Journal of Affective Disorders